Verve Therapeutics announced the appointment of Frederick “Fred” Fiedorek, M.D., as chief medical officer. Andrew Bellinger, M.D., Ph.D., the current chief scientific officer and CMO, will transition to the role of CSO. Dr. Fiedorek has more than 20 years of experience in clinical development and leadership, primarily in therapeutic areas such as diabetes, cardiovascular disease and endocrine/metabolic diseases. Prior to Verve, he held CMO roles at Rhythm Pharmaceuticals, Intarcia Therapeutics and a stealth company within Atlas Venture.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VERV:
- Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
- Verve Therapeutics price target lowered to $55 from $56 at Guggenheim
- Verve Therapeutics reports Q2 EPS (87c), consensus (92c)
- Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
- Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference